Rapid resolution of inflammatory bowel disease (IBD) symptoms such as abdominal pain, diarrhea, and rectal bleeding, are important for both patients and physicians. These symptoms may affect the patient’s quality of life thereby rapid amelioration is crucial. The data on the rapidity of response is essential for the physicians to make decision regarding the choice of therapy.
A post-hoc study reported that Vedolizumab therapy (Monoclonal Ab) improved patient-reported outcomes within 2 weeks in anti-TNF–naïve patients with ulcerative colitis or Crohn's disease. However, no significant difference was found between the Vedolizumab- and placebo-treated patients who had previously received anti-TNF therapy. Alternatively, drugs such as Tofacitinib, a Janus kinase inhibitor, has been reported to improve ulcerative colitis symptoms within 3 days in both anti-TNF-naïve and TNF…
